-
公开(公告)号:US12128069B2
公开(公告)日:2024-10-29
申请号:US15568683
申请日:2016-04-22
发明人: Steven M. Albelda
IPC分类号: A61K35/17 , A61K9/00 , A61K38/17 , A61K39/00 , A61K39/395 , C07K14/47 , C07K14/705 , C07K14/725 , C07K16/32 , C12N5/0783 , C12N15/85 , A61K45/06 , C12N7/00
CPC分类号: A61K35/17 , A61K9/0019 , A61K38/1709 , A61K38/177 , A61K38/1774 , A61K39/0011 , A61K39/001102 , A61K39/001104 , A61K39/001111 , A61K39/001112 , A61K39/001117 , A61K39/001124 , A61K39/001156 , A61K39/001157 , A61K39/00117 , A61K39/00118 , A61K39/001182 , A61K39/001184 , A61K39/00119 , A61K39/001193 , A61K39/39558 , C07K14/47 , C07K14/7051 , C07K14/70521 , C07K16/32 , C12N15/85 , A61K2039/5154 , A61K2039/54 , A61K2039/572 , A61K45/06 , C07K14/70578 , C07K2317/622 , C07K2317/732 , C07K2319/02 , C07K2319/03 , C07K2319/035 , C12N5/0637 , C12N7/00 , C12N2510/00 , C12N2740/15043
摘要: The invention provides compositions and methods for treating diseases associated with expression of a cancer associated antigen as described herein. The invention also relates to chimeric antigen receptor (CAR) specific to a cancer associated antigen as described herein, vectors encoding the same, and recombinant T cells comprising the CARs of the present invention. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an antigen binding domain that binds to a cancer associated antigen as described herein.
-
公开(公告)号:US20240299518A1
公开(公告)日:2024-09-12
申请号:US18663847
申请日:2024-05-14
发明人: BELINDA SÁNCHEZ RAMÍREZ , GRETCHEN BÁEZ BERGADO , NARJARA GONZÁLEZ SUÁREZ , MABEL CRUZ RODRÍGUEZ , DIANA ROSA HERNÁNDEZ FERNÁNDEZ , LISSET CHAO GARCÍA
CPC分类号: A61K39/001106 , A61K39/001104 , A61P35/00 , A61K2039/55555 , A61K2039/585 , A61K2039/70 , A61K2039/82 , A61K2039/852
摘要: The present invention relates to the branch of Biotechnology and Medicine, particularly to a method for the selection and treatment of patients with carcinomas of epithelial origin that co-express the HER1 and HER2 receptors without increased expression of these receptors or with the presence of RAS activating mutations. In particular, this method is based on the application of bivalent vaccine compositions which have as active principle the extracellular domains of the HER1 and HER2 receptors or portions thereof and as an adjuvant the very small proteoliposomes derived from the outer membrane proteins of Neisseria meningitidis and the GM3 ganglioside. This method is useful for the treatment of patients whose expression levels of HER1 and HER2 do not allow the monoclonal antibodies against HER1 and/or HER2 to have a therapeutic effect.
-
公开(公告)号:US12036272B2
公开(公告)日:2024-07-16
申请号:US18064168
申请日:2022-12-09
IPC分类号: A61K39/00 , A61K35/17 , A61K39/12 , A61K39/145 , A61K39/245 , A61P31/16 , A61P31/22 , A61P35/00 , C12M1/12 , C12N5/00 , C12N5/0783 , C12N7/00
CPC分类号: A61K39/0011 , A61K35/17 , A61K39/001104 , A61K39/001106 , A61K39/001112 , A61K39/001113 , A61K39/001114 , A61K39/001124 , A61K39/001168 , A61K39/001182 , A61K39/001195 , A61K39/12 , A61K39/145 , A61K39/245 , A61P31/16 , A61P31/22 , A61P35/00 , C12M25/14 , C12N5/0636 , C12N7/00 , A61K2039/5154 , A61K2039/5158 , A61K2039/55527 , A61K2039/55533 , A61K2039/605 , A61K2039/6087 , A61K2039/645 , C12N2501/2302 , C12N2501/2315 , C12N2501/2321 , C12N2501/50 , C12N2533/70 , C12N2710/16134 , C12N2710/16234 , C12N2760/16034
摘要: The present invention relates to artificial antigen presenting cell (aAPC) scaffolds to provide cells with specific functional stimulation to obtain phenotypic and functional properties ideal to mediate tumor regression or viral clearance. In particular, the scaffolds of the present invention comprise antigens, such as peptide-MHC (pMHC) class I molecules, and specific combinations of cytokines and co-stimulatory molecules to allow effective expansion and functional stimulation of specific T cells.
-
4.
公开(公告)号:US20240124540A1
公开(公告)日:2024-04-18
申请号:US18516360
申请日:2023-11-21
申请人: Advaxis, Inc.
CPC分类号: C07K14/4748 , A61K35/74 , A61K39/0011 , A61K39/001103 , A61K39/001104 , A61K39/001107 , A61K39/00115 , A61K39/001157 , A61K39/001186 , A61K39/001188 , A61K39/001189 , A61K39/001194 , A61K39/001195 , C12N15/74 , A61K2039/523 , A61K2039/55544 , A61K2039/55594 , A61K2039/645 , C07K2319/43 , C07K2319/95
摘要: Provided herein are recombinant fusion polypeptides comprising one or more antigenic peptides (e.g., fused to a PEST-containing peptide) from cancer-associated proteins. The antigenic peptides can comprise one or more or all of an antigenic peptide comprising a recurrent cancer mutation, an antigenic peptide comprising a heteroclitic mutation, or an antigenic peptide fused to a ubiquitin protein. For example, provided herein are recombinant fusion polypeptides comprising two or more antigenic peptides (e.g., fused to a PEST-containing peptide), wherein each antigenic peptide comprises a recurrent cancer mutation, and wherein at least two of the antigenic peptides are fragments of the same cancer-associated protein. Also provided are nucleic acids encoding such fusion polypeptides, recombinant bacteria or Listeria strains comprising such fusion polypeptides or such nucleic acids, and cell banks comprising such recombinant bacteria or Listeria strains. Also provided herein are methods of generating such fusion polypeptides, such nucleic acids, and such recombinant bacteria or Listeria strains. Also provided are immunogenic compositions, pharmaceutical compositions, and vaccines comprising such fusion polypeptides, such nucleic acids, or such recombinant bacteria or Listeria strains. Also provided are methods of inducing an anti-tumor-associated-antigen immune response in a subject, methods of inducing an anti-tumor or anti-cancer immune response in a subject, methods of treating a tumor or cancer in a subject, methods of preventing a tumor or cancer in a subject, and methods of protecting a subject against a tumor or cancer using such recombinant fusion polypeptides, nucleic acids, recombinant bacteria or Listeria strains, immunogenic compositions, pharmaceutical compositions, or vaccines.
-
公开(公告)号:US11680244B2
公开(公告)日:2023-06-20
申请号:US15575073
申请日:2016-05-19
IPC分类号: C12N5/10 , C12N5/0784 , A61K39/00
CPC分类号: C12N5/0639 , A61K39/0011 , A61K39/00115 , A61K39/00117 , A61K39/001104 , A61K39/001106 , A61K39/001108 , A61K39/001109 , A61K39/001122 , A61K39/001149 , A61K39/001151 , A61K39/001153 , A61K39/001156 , A61K39/001157 , A61K39/001164 , A61K39/001168 , A61K39/001171 , A61K39/001172 , A61K39/001182 , A61K39/001186 , A61K39/001188 , A61K39/001191 , A61K39/001192 , A61K39/001193 , A61K39/001194 , A61K39/001195 , A61K39/001197 , A61K2039/5154 , C12N2500/30 , C12N2501/125 , C12N2501/145 , C12N2501/22 , C12N2501/2303 , C12N2501/26 , C12N2501/42 , C12N2501/998 , C12N2502/1121 , C12N2502/1171 , C12N2502/1352
摘要: In various embodiments methods of producing a cell population enriched for CLEC9A+ dendritic cells are provided where the methods involve culturing stem cells and/or progenitor cells in a cell culture comprising culture medium, a notch ligand, stem cell factor (SCF), FLT3 ligand (FLT3L); thrombopoietin (TPO); and IL-3 and/or GMCSF.
-
公开(公告)号:US20170080104A1
公开(公告)日:2017-03-23
申请号:US15236186
申请日:2016-08-12
发明人: Darrell J. IRVINE , Yiran ZHENG , Li Tang
IPC分类号: A61K9/127 , A61K39/00 , C07K14/55 , C07K16/30 , C07K14/705 , C07K14/725 , C12N5/0783 , C07K19/00
CPC分类号: A61K39/0011 , A61K9/127 , A61K39/001104 , A61K47/60 , A61K47/6849 , A61K47/6889 , A61K47/6903 , A61K47/6913 , A61K2039/505 , A61K2039/5156 , A61K2039/5158 , A61K2039/55527 , A61K2039/55533 , A61K2039/57 , A61K2039/585 , A61P35/00 , C07K14/5443 , C07K14/55 , C07K14/70503 , C07K14/7051 , C07K14/70517 , C07K14/70578 , C07K14/70589 , C07K14/7155 , C07K16/2806 , C07K16/2845 , C07K16/289 , C07K16/30 , C07K19/00 , C07K2317/622 , C07K2319/00 , C07K2319/03 , C07K2319/30 , C07K2319/33 , C07K2319/70 , C12N5/0006 , C12N5/0636 , C12N5/0638 , C12N2501/2315
摘要: The present disclosure is directed, in some embodiments, to methods and compositions of comprising a cell having a non-internalizing receptor, and a nanoparticle surface-modified with a ligand that binds to the non-internalizing receptor.
-
公开(公告)号:US20240307534A1
公开(公告)日:2024-09-19
申请号:US18734042
申请日:2024-06-05
申请人: Genentech, Inc.
发明人: Jane L. GROGAN
IPC分类号: A61K39/395 , A61K31/7088 , A61K38/00 , A61K38/19 , A61K38/20 , A61K38/21 , A61K39/00 , A61K45/06 , A61K47/68 , A61P35/00 , C07K16/28 , C07K16/30 , C12N15/113 , C12N15/115
CPC分类号: A61K39/39558 , A61K31/7088 , A61K38/00 , A61K38/193 , A61K38/20 , A61K38/217 , A61K39/0011 , A61K39/001104 , A61K39/001106 , A61K39/001109 , A61K39/001113 , A61K39/001119 , A61K39/001124 , A61K39/001128 , A61K39/001129 , A61K39/001138 , A61K39/00114 , A61K39/001141 , A61K39/001166 , A61K39/00117 , A61K45/06 , A61K47/6803 , A61K47/6851 , A61P35/00 , C07K16/2803 , C07K16/30 , C12N15/1138 , C12N15/115 , A61K2039/505 , A61K2039/5158 , A61K2039/545 , C07K2317/51 , C07K2317/515 , C07K2317/56 , C07K2317/76 , C12N2310/11 , C12N2310/12 , C12N2310/14 , Y02A50/30
摘要: The present disclosure provides methods comprising administering to the individual an effective amount of an agent that decreases or inhibits TIGIT expression and/or activity and an anti-cancer agent and/or an anti-cancer therapy. Further provided are kits comprising an anti-cancer agent, an agent that decreases or inhibits TIGIT expression and/or activity, or both, as well as instructions for use thereof.
-
公开(公告)号:US20240269249A1
公开(公告)日:2024-08-15
申请号:US18443459
申请日:2024-02-16
申请人: Receptos LLC
发明人: Sarah Harris , Erin Babcock , Cristian Rodriguez
CPC分类号: A61K39/001104 , A61K9/0019 , A61P17/04
摘要: The present disclosure is directed to methods of treating atopic dermatitis comprising administering to a subject in need thereof a therapeutically effective amount of an anti-IL-13 antibody, or antigen binding fragment thereof, thereby treating atopic dermatitis in the subject.
-
公开(公告)号:US11964005B2
公开(公告)日:2024-04-23
申请号:US17696028
申请日:2022-03-16
申请人: Receptos LLC
发明人: Sarah Harris , Erin Babcock , Cristian Rodriguez
CPC分类号: A61K39/001104 , A61K9/0019 , A61P17/04
摘要: The present disclosure is directed to methods of treating atopic dermatitis comprising administering to a subject in need thereof a therapeutically effective amount of an anti-IL-13 antibody, or antigen binding fragment thereof, thereby treating atopic dermatitis in the subject.
-
公开(公告)号:US11826372B2
公开(公告)日:2023-11-28
申请号:US17543247
申请日:2021-12-06
申请人: ABIVAX
IPC分类号: A61K31/553 , A61P31/00 , A61P35/00 , A61K39/00 , A61K39/39 , A61K39/395 , C07K16/28 , A61K45/06
CPC分类号: A61K31/553 , A61K39/0011 , A61K39/001104 , A61K39/001106 , A61K39/001124 , A61K39/001129 , A61K39/001135 , A61K39/001174 , A61K39/39 , A61K39/39558 , A61P31/00 , A61P35/00 , C07K16/2818 , A61K45/06 , A61K2039/505 , A61K2039/545 , A61K2039/55516 , A61K2039/55572
摘要: An antitumor pharmaceutical combination includes (i) a compound ABX196 and (ii) at least one chemotherapeutic agent and/or at least one immunotherapeutic agent, for use in the treatment of cancer.
-
-
-
-
-
-
-
-
-